Compounds and compositions as protein kinase inhibitors
US7745437B2 · kind B2 · utility
70Cited by
1References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 9, 2005 |
| Grant date | Jun 29, 2010 |
| Priority date | — |
| Expiry date | Jun 25, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, PDGF-R, trkB, c-SRC, BMX, FGFR3, b-RAF, ΣΓK, Tιε2, Λχκ, θNK2α2, MKK4, c-RAF, MKK6, SAPK2α and SAPK2β kinases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.